ERBB2 and neoplasm: Evaluation of residual disease by MRI was previously shown to depend on tumor phenotype with a lower rate of underestimation in solid tumors positive for HER2, negative for HR, and triple-negative subtype compared to HR+/HER2− tumors that frequently present as non-mass/diffuse enhancement [24, 25].